About Orgenesis (OTCMKTS:ORGS)
Orgenesis Inc. is a regenerative therapy company. The Company operates through two segments: Contract Development and Manufacturing Organization (CDMO) and Cellular Therapy Business (CTB). The CDMO activity is operated by the Company's subsidiary, MaSTherCell SA, which specializes in cell therapy development for advanced medicinal products. MaSTherCell is providing two types of services to its customers: process and assay development services and good manufacturing practice (GMP) contract manufacturing services. The CTB activity is based on its technology that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating (converting) them into pancreatic beta cell-like insulin producing cells for patients with Type I Diabetes. It intends to advance a product that combines cell-based therapy and regenerative medicine, Autologous Insulin Producing (AIP) cells, into clinical development.
Industry, Sector and Symbol
Industry Business Services
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$6.39 million
Price / Sales6.95
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
Orgenesis (OTCMKTS:ORGS) Frequently Asked Questions
What is Orgenesis' stock symbol?
Orgenesis trades on the OTCMKTS under the ticker symbol "ORGS."
Who are some of Orgenesis' key competitors?
Some companies that are related to Orgenesis include Helios and Matheson Analytics (HMNY), Aradigm (ARDM), Aeglea Bio Therapeutics (AGLE), Leap Therapeutics (LPTX), MEI Pharma (MEIP), Opexa Therapeutics (ACER), Five Star Senior Living (FVE), Brainstorm Cell Therapeutics (BCLI), Apollo Endosurgery (APEN), Lipocine (LPCN), Aevi Genomic Medicine (GNMX), Joint (JYNT), Versartis (VSAR), Novan (NOVN), ContraFect (CFRX), Vernalis (VNLPY), PURE Bioscience (PURE) and ADMA Biologics (ADMA).
Who are Orgenesis' key executives?
Orgenesis' management team includes the folowing people:
- Vered Caplan, Chairman of the Board, Chief Executive Officer, President; Chief Executive Officer of Orgenesis Maryland Inc. (Age 46)
- Neil T. Reithinger CPA, Chief Financial Officer, Treasurer, Secretary (Age 46)
- Sarah Ferber Ph.D., Chief Scientific Officer (Age 60)
- Yaron Adler, Director (Age 44)
- Hugues Bultot, Director
- David Sidransky M.D., Director (Age 56)
- Guy Yachin, Director (Age 47)
Who owns Orgenesis stock?
Orgenesis' stock is owned by many different of retail and institutional investors. Top institutional investors include
THEODORUS II SA
(8.92%). View Institutional Ownership Trends for Orgenesis.
How do I buy Orgenesis stock?
Shares of Orgenesis can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Orgenesis' stock price today?
One share of Orgenesis stock can currently be purchased for approximately $4.50.
How big of a company is Orgenesis?
Orgenesis has a market capitalization of $42.45 million and generates $6.39 million in revenue each year. Orgenesis employs 80 workers across the globe.
How can I contact Orgenesis?
Orgenesis' mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The company can be reached via phone at 480-659-6404 or via email at [email protected]
MarketBeat Community Rating for Orgenesis (ORGS)MarketBeat's community ratings are surveys of what our community members think about Orgenesis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Orgenesis (OTCMKTS:ORGS) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Earnings History for Orgenesis (OTCMKTS:ORGS)
No earnings announcements for this company have been tracked by MarketBeat.com
Orgenesis (OTCMKTS:ORGS) Earnings Estimates
Current Year EPS Consensus Estimate: $-0.13 EPS
Next Year EPS Consensus Estimate: $-0.04 EPS
Dividend History for Orgenesis (OTCMKTS:ORGS)
No dividend announcements for this company have been tracked by MarketBeat.com
Orgenesis (OTCMKTS ORGS) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 0.03%
Orgenesis (OTCMKTS ORGS) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/11/2017||Sca Theodorus||Insider||Sell||5,000,000||$0.25||$1,250,000.00|| |
Orgenesis (OTCMKTS ORGS) News Headlines
Orgenesis (OTCMKTS:ORGS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Orgenesis (OTCMKTS ORGS) Stock Chart for Friday, December, 15, 2017